Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 10/20 | 0.63 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | SRC | P12931 | 5/20 | 0.41 |
| ▸ | NMT1 | P30419 | 1/20 | 0.40 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.40 |
| ▸ | GSK3A | P49840 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4172692 | 0.93 | TGFBR1 (0.63) | TGFBR1SRCPDGFRB | |
| SCHEMBL4175724 | 0.93 | TGFBR1 (0.60) | TGFBR1CA12ABL1CA2CA9 | |
| SCHEMBL4184161 | 0.92 | TGFBR1 (0.61) | TGFBR1CA12ABL1CA2CA9 | |
| SCHEMBL4175912 | 0.88 | TGFBR1 (0.61) | TGFBR1CA12ABL1CA2CA9 | |
| SCHEMBL4170271 | 0.85 | TGFBR1 (0.71) | TGFBR1 | |
| SCHEMBL3949452 | 0.85 | TGFBR1 (0.63) | TGFBR1NMT1 | |
| SCHEMBL4172670 | 0.84 | TGFBR1 (0.69) | TGFBR1 | |
| SCHEMBL3951081 | 0.84 | TGFBR1 (0.62) | TGFBR1CA12ABL1CA2CA9 | |
| SCHEMBL4177684 | 0.84 | TGFBR1 (0.68) | TGFBR1 | |
| SCHEMBL4174942 | 0.83 | TGFBR1 (0.67) | TGFBR1NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048269-A1 | CHEMICAL COMPOUNDS-821 | ASTRAZENECA AB (SE) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048269-A1 | CHEMICAL COMPOUNDS-821 | TGFBR1, TGFBR2, SMAD3 | TGFBR1 1/4885NAMPT 2571/4885CA12 590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.